DENVER, March 03, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) (“BioScrip” or the “Company”) today announced its fourth quarter and full-year 2016 financial results. For the fourth quarter, the Company reported revenue from continuing operations of $240.1 million, net loss from continuing operations of ($5.2) million and diluted EPS of ($0.06) loss per share.  For the full-year 2016, the Company reported revenue from continuing operations of $935.6 million, net loss from continuing operations of ($34.4) million and diluted EPS of ($0.46) loss per share.

 

Fourth Quarter Highlights

Net revenue for the fourth quarter 2016 was $240.1 million, a decrease of $3.6 million or 1.5% year over year, reflecting the ongoing favorable shift in revenue mix to a greater percentage of core revenue and less lower-margin non-core revenue;

TUCSON, Ariz., and VENLO, the Netherlands, Nov. 16, 2016 -- HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (QGEN) (Frankfurt Stock Exchange:QIA); “QIAGEN”), announced a Master Assay Development, Commercialization and Manufacturing Agreement (“Agreement”).  This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology.  Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock.

BEDFORD, Mass., Nov. 03, 2016 -- ConforMIS, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the third quarter ended September 30, 2016.

 

Q3 Summary:

Total revenue of $18.6 million, up 34% year-over-year on a reported basis and up 35%  year-over-year on a constant currency basis.
Product revenue of $18.4 million, up 36% year-over-year on a reported basis and up 37% year-over-year on a constant currency basis

U.S. product revenue increased 43% year-over-year
Rest of World product revenue increased 14% year-over-year on a reported basis and 18% year-over-year on a constant currency basis

MINNEAPOLIS, Nov. 02, 2016  -- Skyline Medical Inc. (SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces that it has agreed to grant GLG Pharma, LLC (“GLG”) exclusive rights to market and distribute the STREAMWAY® System in Poland and certain other countries in Central Europe.  This builds upon a previously announced arrangement granting GLG exclusive rights to market and distribute STREAMWAY in the U.K. and an initial agreement to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures.

 

GLG will be responsible for all sales and marketing activities, including hiring and training the appropriate number of direct sales representatives to cover the 3,800 operating rooms in Poland.  Marketing is expected to begin immediately upon receipt of the CE Mark and will be managed from GLG’s facility in Gdansk, Poland.